|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Actelion |
| Information provided by: | Actelion |
| ClinicalTrials.gov Identifier: | NCT00070590 |
Purpose
Clinical and experimental studies suggest that bosentan could delay the progression of interstitial lung disease (ILD) associated with systemic sclerosis (SSc), a condition for which no established efficacious treatment is available. The present trial investigates a possible use of oral bosentan, which is currently approved for the treatment of symptoms of pulmonary arterial hypertension (PAH) WHO Class III and IV, to a new category of patients suffering from ILD associated with SSc.
| Condition | Intervention | Phase |
|
Pulmonary Fibrosis Scleroderma, Systemic |
Drug: Bosentan |
Phase II Phase III |
| MedlinePlus related topics: | Pulmonary Fibrosis Scleroderma |
| Drug Information available for: | Bosentan |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
| Official Title: | A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Efficacy, Safety and Tolerability of Bosentan in Patients With Interstitial Lung Disease Associated With Systemic Sclerosis |
| Estimated Enrollment: | 132 |
| Study Start Date: | July 2003 |
| Estimated Study Completion Date: | September 2005 |
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Main inclusion criteria:
Main exclusion criteria:
Contacts and Locations![]() |
Show 29 Study Locations |
| Actelion |
More Information
| Study ID Numbers: | AC-052-330, BUILD 2 |
| First Received: | October 6, 2003 |
| Last Updated: | November 26, 2008 |
| ClinicalTrials.gov Identifier: | NCT00070590 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|